Cytovia Therapeutics

44 articles about Cytovia Therapeutics

• CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)

  4/7/2020

  Cytovia Therapeutics (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer and infectious diseases, announced today that it is expanding its programs to help urgently address the current SAR CoV2 (COVID-19) crisis. Natural Killer cells are a first line of defense not only against tumor cells but also against severe acute infectious diseases. Using a bi-functional approach has

• Hebrew University to Collaborate with Cytovia Therapeutics Strategic Partnership Aims to Develop Cancer Immunotherapies Targeting Natural Killer Cells

  3/18/2020

  Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company engaged in the development of immunotherapies targeting Natural Killer (NK) cells, announced today a strategic collaboration in the development of precision medicines for both blood cancers and solid tumors.

• CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics

  1/9/2020

  Research teams will use stem cell and gene editing technologies to advance NK cell-based therapies for cancer

• Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy

  1/6/2020

  Cytovia Therapeutics, a biopharmaceutical company, and the University of California, San Francisco (UCSF) announced today that they have entered a 3-year research partnership to develop novel precision gene editing to improve the performance, safety and persistence of Natural Killer (NK) cells and Chimeric Antigen Receptor (CAR)-NK cells.